Targeting Hypoxia-Inducible Factor in the Management of Anemia in Patients with CKD: An Update on Emerging Therapies Evaluation (ID: i774a) Survey

Question Title

* 1. After participating in this activity, how confident are you in the management of patients with anemia with CKD in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 2. What is your degree?

MD/DO

Other (please specify)

Question Title

* 3. How many years have you been in practice?

>21

11-20

1-10

Question Title

* 4. How many patients with anemia with CKD do you manage?

1 to 25

26 to 50

51 to 100

100+

I am not directly involved in patient care

Question Title

* 5. Please select the option that best describes your practice setting.

Academic medical center

Community hospital or medical center

VA, DOD or other government

Managed Care

Research

Pharmaceutical industry

Question Title

* 6. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 7. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 8. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Knowledge regarding prevalence of and burden associated with anemia in patients with CKD

Knowledge of the importance of conservative dosing with ESA therapy

Knowledge of the problems surrounding ESA hyporesponsiveness

An understanding of the pathogenic mechanisms involved in anemia associated with CKD

An understanding of the roles of inflammation, hepcidin, and the HIF pathway

Knowledge of clinical trial outcomes on the use of HIF-PHIs in patients with anemia/CKD

Knowledge of ongoing clinical development of HIF-PHIs, including completion of phase 3 trials and roxadustat’s PDUFA date

An understanding of the place of HIF-PHIs in the management of anemia in CKD

Strategies for determining patients who would be candidates for HIF-PHI therapy

Question Title

* 9. What barriers do you see to making changes in your practice?

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating

After participating in today’s activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Summarize the prevalence of and burden associated with anemia in patients with CKD, particularly those who are hyporesponsive to ESA therapy	Summarize the prevalence of and burden associated with anemia in patients with CKD, particularly those who are hyporesponsive to ESA therapy Strongly agree	Summarize the prevalence of and burden associated with anemia in patients with CKD, particularly those who are hyporesponsive to ESA therapy Agree	Summarize the prevalence of and burden associated with anemia in patients with CKD, particularly those who are hyporesponsive to ESA therapy Neutral	Summarize the prevalence of and burden associated with anemia in patients with CKD, particularly those who are hyporesponsive to ESA therapy Disagree	Summarize the prevalence of and burden associated with anemia in patients with CKD, particularly those who are hyporesponsive to ESA therapy Strongly disagree
Articulate the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway	Articulate the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway Strongly agree	Articulate the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway Agree	Articulate the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway Neutral	Articulate the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway Disagree	Articulate the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway Strongly disagree
Describe the clinical utility of measuring hepcidin levels in patients with anemia and CKD	Describe the clinical utility of measuring hepcidin levels in patients with anemia and CKD Strongly agree	Describe the clinical utility of measuring hepcidin levels in patients with anemia and CKD Agree	Describe the clinical utility of measuring hepcidin levels in patients with anemia and CKD Neutral	Describe the clinical utility of measuring hepcidin levels in patients with anemia and CKD Disagree	Describe the clinical utility of measuring hepcidin levels in patients with anemia and CKD Strongly disagree
Interpret outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD	Interpret outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Strongly agree	Interpret outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Agree	Interpret outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Neutral	Interpret outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Disagree	Interpret outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Strongly disagree

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.

Jay Wish, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 12. The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activity for anemia in CKD or related disease states

Question Title

* 1. After participating in this activity, how confident are you in the management of patients with anemia with CKD in your practice?

Question Title

* 2. What is your degree?

Question Title

* 3. How many years have you been in practice?

Question Title

* 4. How many patients with anemia with CKD do you manage?

Question Title

* 5. Please select the option that best describes your practice setting.

Question Title

* 6. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 7. Which of the following best describes the impact of this activity on your performance?

Question Title

* 8. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 9. What barriers do you see to making changes in your practice?

Question Title

* 10. Please rate your level of agreement by checking the appropriate ratingAfter participating in today’s activity, I am now able to:

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating. Jay Wish, MD, effectively:

Question Title

* 12. The content presented:

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activity for anemia in CKD or related disease states

Question Title

* 15. If you indicated that you perceived commercial bias or influence, please describe:

* 10. Please rate your level of agreement by checking the appropriate rating

After participating in today’s activity, I am now able to:

* 11. Please rate your level of agreement by checking the appropriate rating.

Jay Wish, MD, effectively: